Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Lotus Eye Hospital and Institute Temettü
Temettü kriter kontrolleri 0/6
Lotus Eye Hospital and Institute does not currently pay a dividend.
Anahtar bilgiler
0%
Temettü verimi
0%
Ödeme oranı
| Sektör ortalama getirisi | 0.3% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | ₹0.500 |
| Hisse başına kazanç | ₹1.04 |
| Temettü verim tahmini | n/a |
Son temettü güncellemeleri
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 08
Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 02Recent updates
Optimistic Investors Push Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) Shares Up 25% But Growth Is Lacking
Aug 21Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings
Jan 24Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 08We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Jul 15Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors
Apr 07We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease
Oct 08Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50
Sep 02If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity
Jun 17MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Mar 11Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)
Dec 30Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares
Nov 20The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares
Sep 21Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E
Aug 27
Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?
Aug 03Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises
Jul 06Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if LOTUSEYE's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if LOTUSEYE's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
| Lotus Eye Hospital and Institute Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (LOTUSEYE) | 0% |
| Pazarın Alt %25'i (IN) | 0.2% |
| Pazarın En İyi %25'i (IN) | 1.0% |
| Sektör Ortalaması (Healthcare) | 0.3% |
| Analist tahmini (LOTUSEYE) (3 yıla kadar) | n/a |
Önemli Temettü: Unable to evaluate LOTUSEYE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate LOTUSEYE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: LOTUSEYE is not paying a notable dividend for the Indian market.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as LOTUSEYE has not reported any payouts.